54th Tysabri infusion report...,
Hi everyone, I completed my 54th Tysabri infusion on Tuesday 11/23, and I have been on this medication for more than four years, remaining relapse free all the time, with Tysabri slowing my disease process down, for I surely would be bedridden by now without Tysabri - and for this, I am extremely thankful, especially at this time of year.
Natalizumab Treatment Report
Category: Prescription Drugs
Most Popular Brands: Tysabri
Generic Name: Natalizumab
What is Natalizumab?
Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. It is currently sold under the brand name Tysabri.
Reasons taken & Efficacy
| Reasons taken | Efficacy | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Multiple Sclerosis MS | 1043 |  |  |  |  |  | 373 |
| Other | 33 | | | | | | 10 |
| Fatigue | 23 | | | | | 12 | |
| General health | 22 | | | | 5 | ||
| Improve mobility | 21 | | | | | | 11 |
| Stiffness/Spasticity | 19 | | | | | | 8 |
See all 1148 patients currently taking Natalizumab
Mouse over the table for more information
Side Effects
Dosages
Top 10 dosages based on patients currently taking Natalizumab. See all 24 dosages ►
Stop Reasons
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Doctor's advice | 88 |  | |
| Side effects too severe | 84 | | |
| Other | 81 | | |
| Did not seem to work | 72 | | |
| Personal research | 20 | | |
| Expense | 19 | | |
| Course of treatment ended | 6 | | |
| Change in health plan coverage | 6 | | |
| Not indicated | 2 | |
Duration Hide details ▲
Adherence, Burden & Cost Hide details ▲
Adherence
Taking treatment as prescribed
Adherence of Natalizumab
| Always | 383 | 95% |  |
|---|---|---|---|
| Usually | 14 | 3% |  |
| Sometimes | 3 | 1% |  |
| Never | 5 | 1% |  |
Burden
Difficulty being on treatment
Burden of Natalizumab
| Very | 19 | 5% |  |
|---|---|---|---|
| Somewhat | 48 | 12% |  |
| A little | 116 | 29% |  |
| Not at all | 222 | 55% |  |
Cost
Paid out of pocket
Cost of Natalizumab
| $200+ | 69 | 24% |  |
|---|---|---|---|
| position: absolute;00-199 | 22 | 8% |  |
| $50-99 | 23 | 8% |  |
| $25-49 | 28 | 10% |  |
| < $25 | 136 | 48% |  |
See more information, including instructions, precautions, side effects, and interactions.
Patient Evaluations
See all 405 patient evaluations
-
- msladyinca
- Sex: F
- Sensation: Moderate
- Overall: Mild
- Cognition: none
- Vision: none
- Speech: none
- Swallowing: none
- Upper limb: moderate
- Walking: severe
- See profile
-
- msladyinca
- 300 mg/15 mL every 4 weeks
- since Sep 28, 2010
- Efficacy Major
for To prevent further relapses and slow the disease process down - Side Effects None
- Advice/Tips I'm still relapse free as of October 16th, 2006. My MS is still stable and my infusion next month will mark my treatment time being as more than four years,... See full evaluation
-
- syl
- Sex: F
- Sensation: Moderate
- Overall: Mild
- Cognition: moderate
- Vision: moderate
- Speech: mild
- Swallowing: mild
- Upper limb: moderate
- Walking: moderate
- See profile
-
- syl
- 300 mg/15 mL monthly
- since Jun 02, 2010
- Efficacy Major for Multiple Sclerosis MS
- Side Effects Mild
- Advice/Tips My dr and I recently made the decision to switch my infusions from every 28 days to every 6 wks. We based this decision on the number of infusions I had tak... See full evaluation
-
- teejaygrl
- Sex: F
- Sensation: Moderate
- Overall: Mild
- Cognition: mild
- Vision: mild
- Speech: mild
- Swallowing: mild
- Upper limb: moderate
- Walking: mild
- See profile
-
- teejaygrl
- 300 mg/15 mL monthly
- since Jul 20, 2010
- Efficacy Major for Multiple Sclerosis MS
- Side Effects Mild
- Advice/Tips THIS DRUG HAS HELPED ME GET MY LIFE BACK. I DON'T FEEL SO DOWN AND USELESS. SO MANY PEOPLE HAS SEEN SUCH A DIFFERENCE IN ME AND SO HAVE I. I REALLY DO FEEL A... See full evaluation
See all 405 patient evaluations
Report created on November 24, 2010.
posted by Lauren @ 2:57 PM
5 comments
